Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 1-Year Low – Time to Sell?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $21.46 and last traded at $21.7530, with a volume of 1536019 shares. The stock had previously closed at $22.90.

Analyst Upgrades and Downgrades

Several research analysts have commented on ADPT shares. TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Wednesday. Guggenheim increased their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. JPMorgan Chase & Co. dropped their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Finally, Morgan Stanley boosted their target price on Adaptive Biotechnologies from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and an average target price of $20.83.

Adaptive Biotechnologies Stock Performance

The stock has a market cap of $3.67 billion, a PE ratio of -69.45 and a beta of 2.07. The company’s 50-day moving average price is $17.59 and its two-hundred day moving average price is $16.22.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. During the same period in the previous year, the business earned ($0.20) earnings per share. The firm’s quarterly revenue was up 35.1% compared to the same quarter last year. Equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current fiscal year.

Insider Transactions at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, COO Julie Rubinstein sold 30,941 shares of the company’s stock in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $14.66, for a total value of $453,595.06. Following the completion of the sale, the chief operating officer owned 395,146 shares of the company’s stock, valued at $5,792,840.36. This represents a 7.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sharon Benzeno sold 154,768 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $21.14, for a total transaction of $3,271,795.52. Following the transaction, the insider owned 221,278 shares in the company, valued at $4,677,816.92. The trade was a 41.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 920,545 shares of company stock valued at $18,588,281 over the last 90 days. Company insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently made changes to their positions in the business. 1492 Capital Management LLC purchased a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at approximately $1,484,000. Jupiter Asset Management Ltd. grew its stake in Adaptive Biotechnologies by 33.8% in the fourth quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock worth $5,892,000 after purchasing an additional 91,683 shares during the period. Rhenman & Partners Asset Management AB grew its stake in Adaptive Biotechnologies by 22.2% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock worth $9,825,000 after purchasing an additional 110,000 shares during the period. Westfield Capital Management Co. LP bought a new position in Adaptive Biotechnologies in the fourth quarter worth $65,942,000. Finally, UBS Group AG raised its holdings in Adaptive Biotechnologies by 101.6% in the fourth quarter. UBS Group AG now owns 511,927 shares of the company’s stock worth $8,314,000 after purchasing an additional 257,947 shares in the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.